- Home
- DMAC vs EM Comparison
DMAC vs EM Comparison
Compare DMAC & EM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- EM
- Stock Information
- Founded
- DMAC 2000
- EM 2017
- Country
- DMAC United States
- EM China
- Employees
- DMAC N/A
- EM N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- EM Other Consumer Services
- Sector
- DMAC Health Care
- EM Consumer Discretionary
- Exchange
- DMAC Nasdaq
- EM Nasdaq
- Market Cap
- DMAC 310.1M
- EM 286.5M
- IPO Year
- DMAC N/A
- EM 2021
- Fundamental
- Price
- DMAC $6.97
- EM $1.36
- Analyst Decision
- DMAC Strong Buy
- EM Hold
- Analyst Count
- DMAC 3
- EM 1
- Target Price
- DMAC $12.33
- EM $1.25
- AVG Volume (30 Days)
- DMAC 443.2K
- EM 1.9M
- Earning Date
- DMAC 11-12-2025
- EM 11-26-2025
- Dividend Yield
- DMAC N/A
- EM N/A
- EPS Growth
- DMAC N/A
- EM N/A
- EPS
- DMAC N/A
- EM N/A
- Revenue
- DMAC N/A
- EM $259,541,587.00
- Revenue This Year
- DMAC N/A
- EM $3.30
- Revenue Next Year
- DMAC N/A
- EM $5.26
- P/E Ratio
- DMAC N/A
- EM N/A
- Revenue Growth
- DMAC N/A
- EM N/A
- 52 Week Low
- DMAC $3.19
- EM $0.50
- 52 Week High
- DMAC $7.49
- EM $1.45
- Technical
- Relative Strength Index (RSI)
- DMAC 66.23
- EM 66.62
- Support Level
- DMAC $6.83
- EM $1.34
- Resistance Level
- DMAC $7.41
- EM $1.37
- Average True Range (ATR)
- DMAC 0.42
- EM 0.03
- MACD
- DMAC 0.06
- EM -0.00
- Stochastic Oscillator
- DMAC 77.88
- EM 78.57
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About EM Smart Share Global Limited
Smart Share Global Ltd is a consumer tech company providing mobile device charging services through an extensive online and offline network in China. It provides service through power banks, placed in POIs operated by location partners, such as entertainment venues, restaurants, shopping centers, hotels, transportation hubs, and public spaces. Geographically, the company generates revenue from the PRC. The company has two segments, the mobile device charging segment and the PV business segment. The company generates the majority of its revenue from the mobile device charging segment.